Selected research
Industry Growth & Trends
Global Anemia Drugs Industry Growth and Trends Forecast to 2032
Market perspective
The global Anemia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anemia Drugs include Eli Lilly, GlaxoSmithKline, Bayer AG, Regen Biopharma, Pieris Pharmaceuticals, Onconova Therapeutics, Mast Therapeutics, GlycoMimetics and Global Blood Therapeutics (GBT), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anemia Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anemia Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anemia Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anemia Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Anemia Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anemia Drugs Market by Company
Eli Lilly
GlaxoSmithKline
Bayer AG
Regen Biopharma
Pieris Pharmaceuticals
Onconova Therapeutics
Mast Therapeutics
GlycoMimetics
Global Blood Therapeutics (GBT)
Fibrogen
Celgene Corporation
Bluebird Bio
Akebia Therapeutics
Acceleron Pharma
Anemia Drugs Segment by Type
Oral
Injection
Anemia Drugs Segment by Application
Aplastic Anemia
Iron Deficiency Anemia
Chronic Kidney Disease related Anemia
Sickle Cell Anemia
Anemia Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anemia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anemia Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Anemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Aplastic Anemia
- Iron Deficiency Anemia
- Chronic Kidney Disease related Anemia
- Sickle Cell Anemia
Companies covered
- Eli Lilly
- GlaxoSmithKline
- Bayer AG
- Regen Biopharma
- Pieris Pharmaceuticals
- Onconova Therapeutics
- Mast Therapeutics
- GlycoMimetics
- Global Blood Therapeutics (GBT)
- Fibrogen
- Celgene Corporation
- Bluebird Bio
- Akebia Therapeutics
- Acceleron Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Anemia Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Anemia Drugs Sales Estimates and Forecasts (2021-2032)
- 1.3 Anemia Drugs Market by Type
- 1.3.1 Oral
- 1.3.2 Injection
- 1.4 Global Anemia Drugs Market Size by Type
- 1.4.1 Global Anemia Drugs Market Size Overview by Type (2021-2032)
- 1.4.2 Global Anemia Drugs Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Anemia Drugs Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Anemia Drugs Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Anemia Drugs Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Anemia Drugs Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Anemia Drugs Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Anemia Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Anemia Drugs Industry Trends
- 2.2 Anemia Drugs Industry Drivers
- 2.3 Anemia Drugs Industry Opportunities and Challenges
- 2.4 Anemia Drugs Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Anemia Drugs Revenue (2021-2026)
- 3.2 Global Top Players by Anemia Drugs Sales (2021-2026)
- 3.3 Global Top Players by Anemia Drugs Price (2021-2026)
- 3.4 Global Anemia Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anemia Drugs Major Company Production Sites & Headquarters
- 3.6 Global Anemia Drugs Company, Product Type & Application
- 3.7 Global Anemia Drugs Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anemia Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anemia Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Anemia Drugs Tier 1, Tier 2, and Tier 3
4 Anemia Drugs Regional Status and Outlook
- 4.1 Global Anemia Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Anemia Drugs Historic Market Size by Region
- 4.2.1 Global Anemia Drugs Sales in Volume by Region (2021-2026)
- 4.2.2 Global Anemia Drugs Sales in Value by Region (2021-2026)
- 4.2.3 Global Anemia Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Anemia Drugs Forecasted Market Size by Region
- 4.3.1 Global Anemia Drugs Sales in Volume by Region (2027-2032)
- 4.3.2 Global Anemia Drugs Sales in Value by Region (2027-2032)
- 4.3.3 Global Anemia Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anemia Drugs by Application
- 5.1 Anemia Drugs Market by Application
- 5.1.1 Aplastic Anemia
- 5.1.2 Iron Deficiency Anemia
- 5.1.3 Chronic Kidney Disease related Anemia
- 5.1.4 Sickle Cell Anemia
- 5.2 Global Anemia Drugs Market Size by Application
- 5.2.1 Global Anemia Drugs Market Size Overview by Application (2021-2032)
- 5.2.2 Global Anemia Drugs Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Anemia Drugs Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Anemia Drugs Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Anemia Drugs Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Anemia Drugs Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Anemia Drugs Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Anemia Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Eli Lilly
- 6.1.1 Eli Lilly Company Information
- 6.1.2 Eli Lilly Business Overview
- 6.1.3 Eli Lilly Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Eli Lilly Anemia Drugs Product Portfolio
- 6.1.5 Eli Lilly Recent Developments
- 6.2 GlaxoSmithKline
- 6.2.1 GlaxoSmithKline Company Information
- 6.2.2 GlaxoSmithKline Business Overview
- 6.2.3 GlaxoSmithKline Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 GlaxoSmithKline Anemia Drugs Product Portfolio
- 6.2.5 GlaxoSmithKline Recent Developments
- 6.3 Bayer AG
- 6.3.1 Bayer AG Company Information
- 6.3.2 Bayer AG Business Overview
- 6.3.3 Bayer AG Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Bayer AG Anemia Drugs Product Portfolio
- 6.3.5 Bayer AG Recent Developments
- 6.4 Regen Biopharma
- 6.4.1 Regen Biopharma Company Information
- 6.4.2 Regen Biopharma Business Overview
- 6.4.3 Regen Biopharma Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Regen Biopharma Anemia Drugs Product Portfolio
- 6.4.5 Regen Biopharma Recent Developments
- 6.5 Pieris Pharmaceuticals
- 6.5.1 Pieris Pharmaceuticals Company Information
- 6.5.2 Pieris Pharmaceuticals Business Overview
- 6.5.3 Pieris Pharmaceuticals Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Pieris Pharmaceuticals Anemia Drugs Product Portfolio
- 6.5.5 Pieris Pharmaceuticals Recent Developments
- 6.6 Onconova Therapeutics
- 6.6.1 Onconova Therapeutics Company Information
- 6.6.2 Onconova Therapeutics Business Overview
- 6.6.3 Onconova Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Onconova Therapeutics Anemia Drugs Product Portfolio
- 6.6.5 Onconova Therapeutics Recent Developments
- 6.7 Mast Therapeutics
- 6.7.1 Mast Therapeutics Company Information
- 6.7.2 Mast Therapeutics Business Overview
- 6.7.3 Mast Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Mast Therapeutics Anemia Drugs Product Portfolio
- 6.7.5 Mast Therapeutics Recent Developments
- 6.8 GlycoMimetics
- 6.8.1 GlycoMimetics Company Information
- 6.8.2 GlycoMimetics Business Overview
- 6.8.3 GlycoMimetics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 GlycoMimetics Anemia Drugs Product Portfolio
- 6.8.5 GlycoMimetics Recent Developments
- 6.9 Global Blood Therapeutics (GBT)
- 6.9.1 Global Blood Therapeutics (GBT) Company Information
- 6.9.2 Global Blood Therapeutics (GBT) Business Overview
- 6.9.3 Global Blood Therapeutics (GBT) Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio
- 6.9.5 Global Blood Therapeutics (GBT) Recent Developments
- 6.10 Fibrogen
- 6.10.1 Fibrogen Company Information
- 6.10.2 Fibrogen Business Overview
- 6.10.3 Fibrogen Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Fibrogen Anemia Drugs Product Portfolio
- 6.10.5 Fibrogen Recent Developments
- 6.11 Celgene Corporation
- 6.11.1 Celgene Corporation Company Information
- 6.11.2 Celgene Corporation Business Overview
- 6.11.3 Celgene Corporation Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Celgene Corporation Anemia Drugs Product Portfolio
- 6.11.5 Celgene Corporation Recent Developments
- 6.12 Bluebird Bio
- 6.12.1 Bluebird Bio Company Information
- 6.12.2 Bluebird Bio Business Overview
- 6.12.3 Bluebird Bio Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Bluebird Bio Anemia Drugs Product Portfolio
- 6.12.5 Bluebird Bio Recent Developments
- 6.13 Akebia Therapeutics
- 6.13.1 Akebia Therapeutics Company Information
- 6.13.2 Akebia Therapeutics Business Overview
- 6.13.3 Akebia Therapeutics Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Akebia Therapeutics Anemia Drugs Product Portfolio
- 6.13.5 Akebia Therapeutics Recent Developments
- 6.14 Acceleron Pharma
- 6.14.1 Acceleron Pharma Company Information
- 6.14.2 Acceleron Pharma Business Overview
- 6.14.3 Acceleron Pharma Anemia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 Acceleron Pharma Anemia Drugs Product Portfolio
- 6.14.5 Acceleron Pharma Recent Developments
7 North America by Country
- 7.1 North America Anemia Drugs Sales by Country
- 7.1.1 North America Anemia Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Anemia Drugs Sales by Country (2021-2026)
- 7.1.3 North America Anemia Drugs Sales Forecast by Country (2027-2032)
- 7.2 North America Anemia Drugs Market Size by Country
- 7.2.1 North America Anemia Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Anemia Drugs Market Size by Country (2021-2026)
- 7.2.3 North America Anemia Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Anemia Drugs Sales by Country
- 8.1.1 Europe Anemia Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Anemia Drugs Sales by Country (2021-2026)
- 8.1.3 Europe Anemia Drugs Sales Forecast by Country (2027-2032)
- 8.2 Europe Anemia Drugs Market Size by Country
- 8.2.1 Europe Anemia Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Anemia Drugs Market Size by Country (2021-2026)
- 8.2.3 Europe Anemia Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Anemia Drugs Sales by Country
- 9.1.1 Asia-Pacific Anemia Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Anemia Drugs Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Anemia Drugs Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Anemia Drugs Market Size by Country
- 9.2.1 Asia-Pacific Anemia Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Anemia Drugs Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Anemia Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Anemia Drugs Sales by Country
- 10.1.1 South America Anemia Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Anemia Drugs Sales by Country (2021-2026)
- 10.1.3 South America Anemia Drugs Sales Forecast by Country (2027-2032)
- 10.2 South America Anemia Drugs Market Size by Country
- 10.2.1 South America Anemia Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Anemia Drugs Market Size by Country (2021-2026)
- 10.2.3 South America Anemia Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Anemia Drugs Sales by Country
- 11.1.1 Middle East and Africa Anemia Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Anemia Drugs Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Anemia Drugs Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Anemia Drugs Market Size by Country
- 11.2.1 Middle East and Africa Anemia Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Anemia Drugs Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Anemia Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Anemia Drugs Value Chain Analysis
- 12.1.1 Anemia Drugs Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Anemia Drugs Production Mode & Process
- 12.2 Anemia Drugs Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Anemia Drugs Distributors
- 12.2.3 Anemia Drugs Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst